Targeting Apoptosis in ALL

• Published in: Current hematologic malignancy reports 2022-04, Vol.17 (2), p.53-60
• Main Authors: Smith, Wesley M., Reed, Daniel R.
• Format: Article
• Language: English
• Subjects: Acute Lymphocytic Leukemias (F El Chaer and M Keng; Geriatrics/Gerontology; Hematology; Medicine; Medicine & Public Health; Oncology; Section Editors; Topical Collection on Acute Lymphocytic Leukemias
• ISSN: 1558-8211; 1558-822X
• DOI: 10.1007/s11899-022-00661-9

Purpose of Review While the treatment of acute lymphoblastic leukemia (ALL) has improved significantly over the last 30 years, the majority of adult patients will have their disease relapse. The BCL-2 gene was initially discovered from follicular lymphoma research; however, the BH3 family of proteins has is emerging to be crucial in patients with ALL due to their reliance on the balance of these pro-apoptotic and anti-apoptotic proteins in the BH3 family. We discuss apoptosis in ALL, the reliance mechanisms, drug development in this space, and areas for future research. Recent Findings The first drugs that were developed to inhibit the BCL-2 pathway include both venetoclax (BCL-2 specific inhibitor) and navitoclax (BCL-2, BCL-XL, and BCL-W). These drugs show promise and have obtained complete remissions, minimal residual disease negative status, and have been used as a bridge to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and chronic lymphocytic leukemia. There are multiple ongoing clinical trials looking to assess the use of BCL-2 inhibition with chemotherapy, targeted therapies, and bi-specific T-cell engager therapies not only in both frontline and relapsed refractory ALL but also in consolidation and maintenance phases. Summary There is still a large need for improvement of ALL outcomes in adult patients. Research has shown that ALL depends on the BCL-2 family of proteins for cell survival and proliferation. Targeting this pathway with BCL-2 inhibition has led to encouraging results, and future research is aimed at incorporating this targeted therapy into current treatment paradigms.